neobookRx
GuidelinesOther guideline

References

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-249. https://doi.org/10.3322/caac.216602. Marima R, Mbeje M, Hull R, Demetriou D, Mtshali N, Dlamini Z. Prostate cancer disparities and management in southern Africa: Insights into practices, norms and values. C

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-249. https://doi.org/10.3322/caac.216602.

  2. Marima R, Mbeje M, Hull R, Demetriou D, Mtshali N, Dlamini Z. Prostate cancer disparities and management in southern Africa: Insights into practices, norms and values. Cancer Manag Res 2022;14:3567-3579. https://doi.org/10.2147/CMAR.S3829033.

  3. Dewar M, Kaestner L, Zikhali Q, Jehle K, Sinha S, Lazarus J. Investigating racial differences in clinical and pathological features of prostate cancer in South African men. S Afr J Surg 2018;56(2):54-58.

  4. Heyns CF, Fisher M, Lecuona A, van der Merwe A. Prostate cancer among different racial groups in the Western Cape: Presenting features and management. S Afr Med J 2011;101(4):267-270. https://doi.org/10.7196/SAMJ.44205.

  5. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: Prostate cancer screening. J Urol 2023;210(1):46-53. https://doi.org/10.1097/JU.00000000000034916.

  6. Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentz JO, Roobol MJ. A European model for an organised risk-stratified early detection programme for prostate cancer. Eur Urol Oncol 2021;4(5):731-739. https://doi.org/10.1016/j.euo.2021.06.006.

  7. Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr follow-up of the European Randomised Study of Screening for Prostate Cancer. Eur Urol 2019;76(1):43-51. https://doi.org/10.1016/j.eururo.2019.02.009.

  8. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localised prostate cancer. N Engl J Med 2016;375(15):1415-1424. https://doi.org/10.1056/NEJMoa16062209.

  9. Wilt TJ, Vo TN, Langsetmo L, et al. Radical prostatectomy or observation for clinically localised prostate cancer: Extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol 2020;77(6):713-724. https://doi.org/10.1016/j.eururo.2020.02.009.

  10. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370(10):932-942. https://doi.org/10.1056/NEJMoa1311593.

  11. Matsukawa A, Yanagisawa T, Bekku K, et al. Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: A systematic review and meta-analysis. Eur Urol Oncol 2024;S2588-9311(23)00292-4. https://doi.org/10.1016/j.euo.2023.12.005.

  12. Krilaviciute A, Becker N, Lakes J, et al. Digital rectal examination is not a useful screening test for prostate cancer. Eur Urol Oncol 2023;6(6):566-573. https://doi.org/10.1016/j.euo.2023.09.008.

  13. Naji L, Randhawa H, Sohani Z, et al. Digital rectal examination for prostate cancer screening in primary care: A systematic review and meta-analysis. Ann Fam Med 2018;16(2):149-154. https://doi.org/10.1370/afm.2205.

  14. Jones D, Friend C, Dreher A, Allgar V, Macleod U. The diagnostic test accuracy of rectal examination for prostate cancer diagnosis in symptomatic patients: A systematic review. BMC Fam Pract 2018;19(1):79. https://doi.org/10.1186/s12875-018-0765-y.

  15. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer – 2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79(2):243-262. https://doi.org/10.1016/j.eururo.2020.09.042.

  16. Sayegh N, Swami U, Jo Y, et al. Race and treatment outcomes in patients with metastatic castration-sensitive prostate cancer. JAMA Netw Open 2023;6(8):e2326546. https://doi.org/10.1001/jamanetworkopen.2023.26546.

  17. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin 2019;69(3):211-233. https://doi.org/10.3322/caac.21555.

  18. Polascik T, Oesterling JE, Partin A. Prostate specific antigen: A decade of discovery – what we have learned and where we are going. J Urology 1999;162(2):293-306. https://doi.org/10.1016/S0022-5347(05)68543-6.

  19. Oesterling JE, Rice DC, Glenski WJ, et al. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993;42(3):276-282. https://doi.org/10.1016/0090-4295(93)90616-i.

  20. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels. JAMA 2003;289(20):2695-2700. https://doi.org/10.1001/jama.289.20.2695.

  21. Nordström T, Adolfsson J, Grönberg H, et al. Repeat prostate-specific antigen tests before prostate biopsy decisions. J Natl Cancer Inst 2016;108(12):djw165. https://doi.org/10.1093/jnci/djw165.

  22. Tchetgen M-B, Song JT, Strawderman M, Jacobsen SJ, Oesterling FE. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996;47(4):511-516. https://doi.org/10.1016/S0090-4295(99)80486-5.

  23. Figueirêdo M de F, Lopes GT, Naidu TG. Digital rectal examination (DRE) does not influence total serum levels of prostate specific antigen (tPSA), in individuals without prostate pathology. Int Braz J Urol 2003;29(5):423-427. https://doi.org/10.1590/S1677-55382003000500006.

  24. Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992;267(16):2227-2228.

  25. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS; Free PSA Study Group. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006;67(4):762-768. https://doi.org/10.1016/j.urology.2005.10.052.

  26. Mottet N, Cornford P, van den Bergh R, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer – limited update March 2023. European Association of Urology, 2023. https://uroweb.org/guideline/prostate-cancer/ (accessed 13 March 2024).

  27. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023. J Urol 2024;211(1):11-19. https://doi.org/10.1097/JU.0000000000003698.

  28. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89(5):2179-2184. https://doi.org/10.1210/jc.2003-030330.

  29. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: Review of available data. J Urol 1996;155(1):3-9.

  30. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81(2):814-819. https://doi.org/10.1210/jcem.81.2.8636309.

  31. Eggener SC, Large MC, Gerber GS, et al. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. Urol Oncol 2013;112(47):925-929. https://doi.org/10.1111/bju.12241.

  32. Government of British Columbia. Prostate Cancer Part 1: Diagnosis and Referral in Primary Care. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/prostate-cancer-part-1 (accessed 2 May 2024).

  33. Gerstenbluth RE, Seftel AD, Hampel N, Oeferein MG, Resnck MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: Is biopsy always required? J Urol 2002;168(5):1990-1993. https://doi.org/10.1016/S0022-5347(05)64279-6.

  34. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part II: Considerations for a prostate biopsy. J Urol 2023;210(1):54-63. https://doi.org/10.1097/JU.0000000000003492.

  35. Jang JY, Kim YS. Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate-specific antigen? Korean J Urol 2012;53(2):82-86. https://doi.org/10.4111/kju.2012.53.2.82.

  36. Heyns CF, Basson J, van der Merwe A, Zarrabi AD. Clinical (non-histological) diagnosis of advanced prostate cancer: Evaluation of treatment outcome after androgen deprivation therapy. S Afr J Surg 2014;52(3):82-85.

  37. Benedict MOA, Steinberg WJ, Claassen FM, Mofolo N. The profile of black South African men diagnosed with prostate cancer in the Free State, South Africa. S Afr Fam Pract 2023;65(1):e1-e10. https://doi.org/10.4102/safp.v65i1.5553.

  38. Heyns CF, Naudé AM, Visser AJ, et al. Early diagnosis of prostate cancer in the Western Cape. S Afr Med J 2001;91(8):679-684.

  39. Rebbeck TR, Devesa SS, Chang B-L, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer 2013;2013:560857. https://doi.org/10.1155/2013/560857.

  40. Marais B, Klopper G, John J. Prostate cancer perspective: Africa versus the world. S Afr Med J 2024;114(4):e1950. https://doi.org/10.7196/SAMJ.2024.v114i4.1950.

  41. Baratedi WM, Tshiamo WB, Mogobe KD, McFarland DM. Barriers to prostate cancer screening by men in sub-Saharan Africa: An integrated review. J Nurs Scholarsh 2020;52(1):85.94. https://doi.org/10.1111/jnu.12529.

  42. John J, Adam A, Mutambirwa S. Urology care in South Africa: A call for collaboration. S Afr Med J 2024;114(4):e2107. https://doi.org/10.7196/SAMJ.2024.v114i4.2107.

  43. John J. Urology pathways for the primary care physician. S Afr Med J 2024;114(4):e1670. https://doi.org/10.7196/SAMJ.2024.v114i4.1670. Accepted 5 April 2024.

Click here to access the pdf.

South African Urology Association and the Prostate Cancer Foundation of South Africa: The South African Prostate Cancer Screening Guidelines (SAMJ_CME)_May 2024, Vol. 114, No. 5

Drugs mentioned

NeoHealth® ID 37832 · updated 4/15/2025